Can inflammatory markers predict response to methotrexate in JIA? Results from the CHARM study

Authors :: Lucy R. Wedderburn
Simona Ursu
Dirk Holzinger
Johannes Roth
F Patrick
Halima Moncrieffe
L Kassoumeri
Source :: Pediatric Rheumatology Online Journal, Pediatric Rheumatology Online Journal, Vol 9, Iss Suppl 1, p O10 (2011)
Publication Year :: 2011
Publisher :: BioMed Central, 2011.
Abstract: Background Juvenile idiopathic arthritis (JIA) is the most common childhood rheumatological disease with an incidence of 1 in 1000. Methotrexate is the primary DMARD given to patients with JIA but approximately 30% of children fail to respond. The SPARKS CHARM study enrolls patients with JIA about to start MTX with the aim to discover predictors of response to MTX, to distinguish patients who will respond well to MTX from non-responders.

Tools